Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Tidewater Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Tidewater Inc trades at $90.62 (market cap $4.46B). The key difference: Tidewater Inc is far larger — about 5.2× Amphastar Pharmaceuticals Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TDW | |
|---|---|---|
Market Cap | $863.95M | $4.46B |
Sector | Health | Utilities |
52-Week High | $30.81 | $91.20 |
52-Week Low | $16.87 | $47.29 |
Enterprise Value | $1.26B | $4.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Tidewater (TDW) trades at $82.84, up 1.56% today, with a bullish technical signal from moving averages and strong support at $81. The company reported Q2 2026 EPS of $0.43, beating estimates, but has missed expectations in recent quarters. Revenue for 2025 was $1.35B with a net income margin of 18.34%, though 2026 projections show a decline to $1.3B and lower margins. Analyst consensus is mixed with 26.92% buy ratings, while institutional holdings saw increases from First Trust Advisors and Bank of New York Mellon in 2026.
Outlook: TDW benefits from operational strength and bullish technicals, but earnings misses and margin compression pose risks. Investors should weigh solid cash flow against competitive and macroeconomic headwinds in the oil and gas sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
